0001104659-21-143846 25 1 20211126 20211126 20211126 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 25 34 001-39202 211450452 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 25 1 tm2133952d1_25.htm 25

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 25

 

NOTIFICATION OF REMOVAL FROM LISTING AND/OR

REGISTRATION UNDER SECTION 12(b) OF THE

SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number: 001-39202

 

ANNOVIS BIO, INC.

NYSE American

(Exact name of Issuer as specified in its charter, and name of Exchange

where security is listed and/or registered)

 

1055 Westlakes Drive, Suite 300

Berwyn, PA 19312
610-727-3913

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

 

Common Stock, par value $0.0001 per share

(Description of class of securities)

 

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

 

¨ 17 CFR 240.12d2-2(a)(1)

 

¨ 17 CFR 240.12d2-2(a)(2)

 

¨ 17 CFR 240.12d2-2(a)(3)

 

¨ 17 CFR 240.12d2-2(a)(4)

 

¨ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1

 

x Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Annovis Bio, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused the notification to be signed on its behalf by the undersigned duly authorized person.

 

Date: November 26, 2021 By: /s/ Jeffrey McGroarty
  Name: Jeffrey McGroarty
  Title: Chief Financial Officer

 

1  Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.